CSPC Pharmaceutical Group

08/03/2022

25/02/2022

Mr. Huang was diagnoses with T-cell lymphoma-associated hemophagocytic syndrome. When he almost lost his hope, Mr. Huang heard about the clinical trial of Mitoxantrone Hydrochloride liposome injection and was involved volunteerly. From being completely unable to take care of himself to be able to go to work, Mr. Huang has survived from desperate situation. Let's learn about Mr. Huang's story from the video below.

15/02/2022

CSPC has won the Title of “Outstanding Contributions in Social Responsibility” in rewards to its fulfillment of social responsibilities in terms of environmental protection, employee benefits and charitable activities. To learn more about CSPC’s actions, please click the following link: https://lnkd.in/gFJE_ZUY.

15/02/2022

Happy Lantern Festival

11/02/2022

On February 8, 2022, CSPC (1093.HK) announced that the Group had completed the acquisition of 100% equity in Zhuhai Zhifan Enterprise Management Consulting Center (Limited Partnership). Zhuhai Zhifan holds approximately 51% of the total registered capital of Recomgen Biotech by the time of this announcement.
Recomgen Biotech's patented self-developed rhTNK-tPA (Recombinant Human TNK Tissue-type Plasminogen Activator for Injection) is a third-generation specific thrombolytic drug, which was launched in China in 2015. The drug is for the thrombolytic therapy for patients with acute myocardial infarction within 6 hours of onset. Its indication for thrombolysis in cerebral infarction was approved for the clinical trial in 2017, and was processed into phase III in 2021 (TRACEII).
To learn more, please visit the following passage: https://lnkd.in/gfnrvbaY #

09/02/2022

On January 27, CSPC (1093. HK) announced that FDA granted Fast Track designation to JMT601 (CPO107), CSPC's first-in-class drug. The drug is intended to treat adults' relapsed or refractory diffuse large B-cell lymphoma. JMT601 (CPO107) is the world's first bispecific SIRPα fusion protein with a synergistic targeted binding effect that has entered the clinical development phase. To learn more, please visit: http://en.e-cspc.com/details/details_215_590.html

19/01/2022

Our volunteers fighting against pandemic.

17/01/2022

CSPC (1093. HK) and Alphamab Oncology (9966. HK) jointly announced the clinical trial registration (KN026-CSP-001) of HER2 bispecific antibody (BsAb) KN026 combined with chemotherapy was officy approved by the Center for Drug Evaluation (CDE). The study aims to evaluate the efficiency and safety of KN026 combined with chemotherapy in HER2-positive gastric cancer patients who failed first-line therapy (including adenocarcinoma of the esophagogastric junction, AEG). To learn more about the study, please click: https://lnkd.in/gmq5KdNM

14/01/2022

Mitoxantrone hydrochloride liposome for injection (10ml:10mg), one of our key innovative product.

12/01/2022

Mitoxantrone hydrochloride liposome for injection (10ml:10mg), our key innovative product, has been launched successfully! This product is a self-developed anti-tumor nano-drug of CSPC as well as the first mitoxantrone nano-drug launched in the world, with its patent for invention granted in more than 10 countries and regions, such as China, the US, Europe and Japan. The product adopts a unique drug loading and releasing technique to ensure that the nanoparticles can effectively converge in the tumors and reasonably release the drug after the drug is administered. In this case, the bioavailability of the drug in the tumors can be enhanced, and the efficacy and safety can be significantly improved. Satisfactory clinical data has been obtained on the first indication PTCL, and multiple clinical trials on solid tumors and large tumors are underway, showing a considerable market potential. To learn more about the product, please visit: http://en.e-cspc.com/details/details_215_580.html

10/01/2022

As the Omicron variant keeps spreading, our thoughts are with those who are impacted. We have already launched the mRNA SARS-CoV-2 vaccine (the Group’s first vaccine product) industrialization project. With RMB 1 billion investment, an mRNA vaccine production line is built up in the early stage. And we will then gradually expand the production based on the market demand. Consistent with our values and role as a leading domestic pharmaceutical company, we always actively respond to the needs of society.
Besides SARS-CoV-2 vaccine, the group is also planning the industrialization project of rabies vaccine for human use, rabies vaccine for animal use, herpes zoster virus vaccine, respiratory syncytial virus vaccine, influenza virus vaccine, among others. The mRNA vaccine industrialization project is one of the key development projects of CSPC in the future, with a planned total investment of RMB 2 billion.

10/01/2022

06/01/2022

Recently, one of the sub-articles in the Conjupri LEADER Study Project, titled "Association between heart rate and major adverse cardiovascular events among 9,991 hypertension patients: a multicenter retrospective follow-up study", has received acceptance from Frontiers in Cardiovascular Medicine and has been published on the Frontiers official site. CSPC keeps exploring stronger evidence-based medical evidence for clinical applications of Conjupri. To learn more please read the following passage: https://lnkd.in/gEk4B2ma

06/01/2022

The market launch of Mitoxantrone Hydrochloride liposome injection is coming soon. Mitoxantrone Hydrochloride liposome injection is a blockbuster strategic product independently developed by CSPC. It opens a new chapter for the treatment of relapsed/refractory PTCL and ENKTCL. Why is Mitoxantrone Hydrochloride liposome injection a new choice for PTCL patients? Please learn more about the product through the following passage: http://en.e-cspc.com/details/details_215_580.html

31/12/2021

On December 29, CSPC (1093.HK) announced that SYHX2001 had been approved for the clinical trial in China by the National Medical Products Administration of the People's Republic of China. This product is a Class I chemical new drug[d1] independently developed by the Group. The clinical indications approved this time are advanced malignant solid tumors and recurrent/refractory hematological tumors. Get more information about the product through the link: http://en.e-cspc.com/details/details_215_581.html